# Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

> **NCT02533765** · PHASE2 · COMPLETED · sponsor: **Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS** · enrollment: 18 (actual)

## Conditions studied

- Neoplasms, Germ Cell and Embryonal

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02533765
- **Lead sponsor:** Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-11
- **Primary completion:** 2018-09
- **Final completion:** 2023-02-13
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02533765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02533765, "Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02533765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*